AR111630A1 - ANTICUERPOS ANTI-SIRPa - Google Patents
ANTICUERPOS ANTI-SIRPaInfo
- Publication number
- AR111630A1 AR111630A1 ARP180101300A ARP180101300A AR111630A1 AR 111630 A1 AR111630 A1 AR 111630A1 AR P180101300 A ARP180101300 A AR P180101300A AR P180101300 A ARP180101300 A AR P180101300A AR 111630 A1 AR111630 A1 AR 111630A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdr1
- cdr2
- cdr3
- seq
- amino acid
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un anticuerpo anti-SIRPa o un fragmento de unión al antígeno del mismo que comprende regiones determinantes de complementariedad (CDR) de la región variable (VR) de cadena pesada (HC) y cadena liviana (LC) seleccionadas del grupo que consiste en: a) secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 3 y secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 4; b) secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 5 y secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 6; c) secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 7 y secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 8; d) secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 9 y secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 10; e) secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 11 y secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 12; f) secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 13 y secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 14; g) secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 15 y secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 16; y h) secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 17 y secuencias de aminoácidos de CDR1, CDR2 y CDR3 de la SEQ ID Nº 18; donde las CDR se determinan de acuerdo con numeración de Kabat. Reivindicación 10: El anticuerpo anti-SIRPa de acuerdo con cualquiera de las reivindicaciones 1 a 8 o la composición farmacéutica de acuerdo con la reivindicación 9 para usar como un medicamento. Reivindicación 11: El anticuerpo anti-SIRPa o la composición farmacéutica para usar de acuerdo con la reivindicación 9 para usar en el tratamiento de tumores sólidos humanos y neoplasias hematológicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171285 | 2017-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111630A1 true AR111630A1 (es) | 2019-07-31 |
Family
ID=58714966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101300A AR111630A1 (es) | 2017-05-16 | 2018-05-16 | ANTICUERPOS ANTI-SIRPa |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11274159B2 (es) |
| EP (2) | EP4400173A3 (es) |
| JP (1) | JP7171617B2 (es) |
| KR (1) | KR102714600B1 (es) |
| CN (2) | CN110799536B (es) |
| AR (1) | AR111630A1 (es) |
| AU (1) | AU2018268304B2 (es) |
| BR (1) | BR112019023754A2 (es) |
| CA (1) | CA3063622A1 (es) |
| CL (1) | CL2019003266A1 (es) |
| DK (1) | DK3625259T3 (es) |
| ES (1) | ES2981193T3 (es) |
| FI (1) | FI3625259T3 (es) |
| HR (1) | HRP20240924T1 (es) |
| HU (1) | HUE067040T2 (es) |
| LT (1) | LT3625259T (es) |
| MX (1) | MX2019013749A (es) |
| MY (1) | MY199247A (es) |
| PL (1) | PL3625259T3 (es) |
| PT (1) | PT3625259T (es) |
| RU (1) | RU2771174C2 (es) |
| TW (1) | TWI710574B (es) |
| WO (2) | WO2018210793A2 (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3443010T2 (ro) | 2016-04-14 | 2024-12-31 | Ose Immunotherapeutics | Noi anticorpi anti-SIRPa și aplicațiile lor terapeutice |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| JP7173971B2 (ja) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| IL315837A (en) * | 2017-04-13 | 2024-11-01 | Sairopa B V | Anti-SIRP-alpha antibodies |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| UA128113C2 (uk) | 2018-05-25 | 2024-04-10 | ЕЛЕКТОР ЕлЕлСі | Анти-sirpa антитіла і способи їхнього застосування |
| SG11202010990TA (en) * | 2018-06-29 | 2020-12-30 | Alector Llc | Anti-sirp-beta1 antibodies and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| MY205933A (en) | 2018-09-27 | 2024-11-21 | Celgene Corp | Sirp-alpha binding proteins and methods of use thereof |
| SG11202104431PA (en) * | 2018-11-15 | 2021-05-28 | Byondis Bv | HUMANIZED ANTI-SIRPα ANTIBODIES |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| AU2020374947C1 (en) | 2019-10-31 | 2025-05-08 | Forty Seven, LLC | Anti-CD47 and anti-CD20 based treatment of blood cancer |
| US20210154269A1 (en) | 2019-11-27 | 2021-05-27 | ALX Oncology Inc. | Combination therapies for treating cancer |
| CN114040925B (zh) * | 2019-12-24 | 2023-04-28 | 礼新医药科技(上海)有限公司 | 抗SIRPα单克隆抗体及其用途 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| CN115190886A (zh) * | 2020-02-20 | 2022-10-14 | 马斯特里赫特大学 | 循环bmp10（骨形态发生蛋白10）的检测方法 |
| TW202208430A (zh) * | 2020-05-08 | 2022-03-01 | 美商電子療法股份有限公司 | ＳＩＲＰα、ＳＩＲＰβ１及ＳＩＲＰγ抗體及其用途 |
| CN115666620A (zh) | 2020-06-01 | 2023-01-31 | Alx肿瘤生物技术公司 | 用于治疗癌症的包含低甲基化剂的联合疗法 |
| CN114560940B (zh) * | 2020-11-27 | 2023-07-14 | 缔码生物科技(武汉)有限公司 | 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用 |
| US20240018255A1 (en) * | 2020-11-30 | 2024-01-18 | Qure Biotechnology (Shanghai) Co., Ltd. | ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| CA3218692A1 (en) | 2021-06-04 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023020459A1 (zh) * | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| CN118119638A (zh) * | 2021-09-03 | 2024-05-31 | 酵活英属哥伦比亚有限公司 | 具有高热稳定性和减弱的效应子功能的fc变体 |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| JP2024546851A (ja) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CA3249472A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | KIRSTEN G12D RAT SARCOMA VIRUS MODULATOR COMPOUNDS |
| JP2025523369A (ja) | 2022-06-01 | 2025-07-23 | エーエルエックス オンコロジー インコーポレイテッド | 尿路上皮癌腫を治療するための併用療法 |
| AU2023298558A1 (en) | 2022-07-01 | 2024-12-19 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220895A1 (en) * | 2023-04-20 | 2024-10-24 | Twist Bioscience Corporation | Antibodies and variant nucleic acid libraries for sirp-alpha |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| CN116715774B (zh) * | 2023-05-12 | 2023-11-24 | 武汉爱博泰克生物科技有限公司 | 针对人axl的兔单克隆抗体及其制备方法和应用 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN118344476B (zh) * | 2024-05-16 | 2024-11-15 | 武汉爱博泰克生物科技有限公司 | 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用 |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118620078B (zh) * | 2024-07-09 | 2024-11-19 | 武汉爱博泰克生物科技有限公司 | 抗人cd45ra蛋白的抗体、抗体偶联物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2001040307A1 (de) * | 1999-11-30 | 2001-06-07 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper gegen signal-regulator-proteine |
| SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| JP5940093B2 (ja) | 2011-01-19 | 2016-06-29 | カンタージア アクチエボラーグ | 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用 |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| PE20142422A1 (es) * | 2012-04-05 | 2015-01-21 | Hoffmann La Roche | Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos |
| CN104487457B (zh) | 2012-05-30 | 2018-01-26 | 中外制药株式会社 | 靶组织特异性抗原结合分子 |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP3116544A4 (en) | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| WO2016187226A1 (en) * | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| JP7078533B2 (ja) * | 2015-10-21 | 2022-05-31 | オーエスイー イムノセラピューティクス | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 |
| WO2017178653A2 (en) * | 2016-04-14 | 2017-10-19 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| AU2017307198B2 (en) | 2016-08-03 | 2024-05-30 | Forty Seven, LLC | Disrupting Fc receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy |
-
2018
- 2018-05-15 DK DK18729328.7T patent/DK3625259T3/da active
- 2018-05-15 CN CN201880032714.7A patent/CN110799536B/zh active Active
- 2018-05-15 PL PL18729328.7T patent/PL3625259T3/pl unknown
- 2018-05-15 KR KR1020197037055A patent/KR102714600B1/ko active Active
- 2018-05-15 HR HRP20240924TT patent/HRP20240924T1/hr unknown
- 2018-05-15 MY MYPI2019006658A patent/MY199247A/en unknown
- 2018-05-15 AU AU2018268304A patent/AU2018268304B2/en active Active
- 2018-05-15 FI FIEP18729328.7T patent/FI3625259T3/fi active
- 2018-05-15 TW TW107116450A patent/TWI710574B/zh active
- 2018-05-15 ES ES18729328T patent/ES2981193T3/es active Active
- 2018-05-15 RU RU2019141289A patent/RU2771174C2/ru active
- 2018-05-15 LT LTEPPCT/EP2018/062473T patent/LT3625259T/lt unknown
- 2018-05-15 WO PCT/EP2018/062473 patent/WO2018210793A2/en not_active Ceased
- 2018-05-15 MX MX2019013749A patent/MX2019013749A/es unknown
- 2018-05-15 WO PCT/EP2018/062477 patent/WO2018210795A1/en not_active Ceased
- 2018-05-15 EP EP24169594.9A patent/EP4400173A3/en active Pending
- 2018-05-15 PT PT187293287T patent/PT3625259T/pt unknown
- 2018-05-15 US US16/614,199 patent/US11274159B2/en active Active
- 2018-05-15 BR BR112019023754A patent/BR112019023754A2/pt unknown
- 2018-05-15 JP JP2019563581A patent/JP7171617B2/ja active Active
- 2018-05-15 CN CN202410367469.2A patent/CN118271443A/zh active Pending
- 2018-05-15 EP EP18729328.7A patent/EP3625259B1/en active Active
- 2018-05-15 CA CA3063622A patent/CA3063622A1/en active Pending
- 2018-05-15 HU HUE18729328A patent/HUE067040T2/hu unknown
- 2018-05-16 AR ARP180101300A patent/AR111630A1/es not_active Application Discontinuation
-
2019
- 2019-11-14 CL CL2019003266A patent/CL2019003266A1/es unknown
-
2022
- 2022-02-02 US US17/591,231 patent/US11718681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| PE20190976A1 (es) | Anticuerpos de union a cd3 | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| CO2017005738A2 (es) | Anticuerpos anti-pd-1 | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| AR105938A1 (es) | Anticuerpo anti-epha4 | |
| AR115192A1 (es) | Anticuerpos | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |